Shuai Li,Yushan Jin,Huanhuan Wu et al.
Shuai Li et al.
Immunotherapy has revolutionized the landscape of cancer treatment, yet its efficacy is often limited by drug resistance, the immunosuppressive tumor microenvironment (TME), and the "undruggable" nature of key immunoregulatory proteins. Tar...
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases [0.03%]
CAR-T疗法治疗自身免疫病的临床应用挑战与策略
Xiaomei Chen,Kaifan Liu,Bowen Liu et al.
Xiaomei Chen et al.
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial efficacy against various hematological malignancies. The remarkable success of CAR-T cell therapy in targeting B-cell malignancies has generated significant interes...
Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets [0.03%]
撤回 notice: 使用 RNA 干扰和药物筛查试验对脂肪肉瘤进行激酶谱分析以确定可用药靶点
Deepika Kanojia,Manoj Garg,Jacqueline Martinez et al.
Deepika Kanojia et al.
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias [0.03%]
DS-1594（MENIN抑制剂）治疗复发/难治性急性白血病的Ⅰ/Ⅱ期临床研究
Jayastu Senapati,Marina Konopleva,Ghayas C Issa et al.
Jayastu Senapati et al.
Several menin inhibitors are in development targeting menin dependent leukemias, however available preclinical results show variable level of activity. We report the phase 1 portion (to establish a recommended phase 2 dose [RP2D]) and pharm...
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025) [0.03%]
免疫检查点抑制剂治疗实体瘤和淋巴瘤（2000-2025年）
Liling Huang,Haohua Zhu,Yuankai Shi
Liling Huang
Cancer immunotherapy originated from the use of Coley's toxins at the end of the nineteenth century. However, immunotherapy had not made great strides in cancer treatment until the discovery of immune checkpoints among which cytotoxic T lym...
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials [0.03%]
葡萄糖苷酶-1受体激动剂和钠-葡萄糖共转运蛋白2抑制剂的使用与妇科肿瘤风险：91项随机对照试验的网状meta分析
Ping-Tao Tseng,Bing-Yan Zeng,Chih-Wei Hsu et al.
Ping-Tao Tseng et al.
Background: Concerns have emerged regarding the oncogenic potential of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors, particularly in relation to gynecologic mali...
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial [0.03%]
纳昔塔马布联合逐步增加剂量的粒细胞-巨噬细胞集落刺激因子治疗原发难治高危神经母细胞瘤I/II期临床试验结果
Brian H Kushner,Shakeel Modak,Audrey Mauguen et al.
Brian H Kushner et al.
Background: With high-risk neuroblastoma, post-induction metastases in bone marrow (BM)/bones confers a poor prognosis but can respond to anti-GD2 antibody, such as naxitamab. We report results of a phase I/II trial. ...
Inflammasomes and pyroptosis in cancer: mechanisms and therapeutic advances [0.03%]
癌症中的炎性小体和细胞焦亡：机制及治疗进展
Wonhyoung Seo,Bokeum Jung,Taylor Roh et al.
Wonhyoung Seo et al.
Inflammasomes are being increasingly recognized for their critical roles in regulating immune cell infiltration, antitumor immunity, and tumorigenesis in cancer biology. The expression and activation of inflammasomes, which vary according t...
Jia Xu,Zhaozhao Chen,Liman Su et al.
Jia Xu et al.
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a highly efficacious treatment for refractory and relapsed hematological malignancies in recent years. However, the complex manufacturing procedures, stringent logistical requi...
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting [0.03%]
CAR-T疗法治疗实体瘤的新进展：2025年ASCO年会最新临床试验成果更新
Wenze Li,Defeng Zhao,Miao Chen et al.
Wenze Li et al.
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated a transformative impact in hematologic malignancies and offers a promising strategy to offer new hope for patients with solid tumors who have failed multiple lines of treatme...